cincodias.elpais.com
Almirall Celebrates 80 Years, Projects Growth with New Dermatology Drug
Founded 80 years ago in Barcelona, the family-owned Almirall pharmaceutical company, specializing in dermatology, anticipates significant growth with its new drug, Ebglyss, projecting €450 million in sales, while its Ilumetri drug shows 25% yearly growth.
- What is the significance of Almirall's new drug, Ebglyss, for the company's future?
- Almirall, a Barcelona-based pharmaceutical company, celebrates its 80th anniversary. The Gallardo family retains 60% ownership, with the rest publicly traded. After overcoming past challenges, Almirall focuses on dermatology, anticipating exponential growth with its new drug, Ebglyss.
- How did Almirall's strategic focus on dermatology contribute to its current success?
- Almirall's strategic shift to dermatology, following the 2014 divestment of its respiratory business to AstraZeneca, is paying off. Investment in R&D, particularly in Ebglyss, and geographic expansion are driving growth. This targeted approach contrasts with past struggles in the US generic market.
- What are the long-term implications of Almirall's family ownership and its impact on the company's strategic decision-making?
- Almirall projects €450 million in sales for Ebglyss, a drug for moderate-to-severe atopic dermatitis. Successful market penetration of Ebglyss, coupled with continued success of Ilumetri (a psoriasis drug with 25% year-on-year growth), positions Almirall for significant future profitability and expansion into new European markets. The company's long-term vision and family ownership contribute to a stable and sustainable growth strategy.
Cognitive Concepts
Framing Bias
The narrative is overwhelmingly positive, emphasizing Almirall's successes and future potential. The headline (not provided but inferred from the content) likely highlights the 80th anniversary and the promising outlook. The interview format allows Carlos Gallardo to present a largely uncritical view of the company's history and strategy. The focus on Ebglyss and the projected 450 million euro sales figure strongly frames the company's future in a positive light.
Language Bias
The language used is largely positive and optimistic, employing terms like "exponencial crecimiento," "mejor fármaco," and "muchas alegrías." These phrases convey a strong sense of confidence and potential. While not inherently biased, they lack the nuance and objectivity of neutral reporting. More measured language could enhance the article's credibility.
Bias by Omission
The article focuses heavily on Almirall's current success and future prospects, particularly the potential of Ebglyss. While mentioning past challenges, it lacks detail on specific setbacks or crises faced during the company's 80-year history. This omission prevents a complete understanding of the company's trajectory and resilience. The article also omits discussion of Almirall's competitors beyond brief mentions of generic competition in the US. A more comprehensive overview of the competitive landscape would provide valuable context.
False Dichotomy
The article presents a somewhat simplified view of Almirall's strategy. The choice between dividend payouts and stock appreciation is framed as an eitheor scenario, neglecting the possibility of balancing both. Furthermore, the focus on Ebglyss and Ilumetri as the key drivers of future growth may overlook other potential avenues for growth or diversification.
Gender Bias
The article focuses solely on Carlos Gallardo, the male president and CEO. While this is understandable given the context of an interview, the complete absence of female voices or perspectives within Almirall creates an implicit bias. The lack of female representation in leadership positions or elsewhere within the company is not addressed.